RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

An interesting hypothesis, so I checked it out. Of the 27 CNS companies I tracked across the full two year period (almost 2 years, starting Jan 1 2007) Cortex placed ninth in price performance. Eight were better, 18 worse. When looking at the mean, its decline of 62.4% was bad, but the mean drop of the entire CNS group was 70%.

So if anything: over a 2 year period, Cortex's price performance was slightly better than the appallingly bad mean performance of its peer group. For whatever that's worth.

The numbers would thus suggest that it is not actually "ugly in comparison to other CNS stocks" over that timeframe. The overall sector--yes, that's been ugly.

NeuroInvestment